Sutro Biopharma, Inc.
STRO
$30.52
$0.973.28%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 14.52M | 11.65M | 9.69M | 63.75M | 17.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.52M | 11.65M | 9.69M | 63.75M | 17.40M |
| Cost of Revenue | 801.00K | 36.64M | 39.85M | 38.33M | 2.28M |
| Gross Profit | 13.72M | -25.00M | -30.16M | 25.42M | 15.12M |
| SG&A Expenses | 7.58M | 8.66M | 8.74M | 10.34M | 13.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.14M | 45.30M | 48.59M | 48.67M | 64.87M |
| Operating Income | -29.61M | -33.66M | -38.90M | 15.08M | -47.47M |
| Income Before Tax | -38.50M | -46.84M | -56.86M | -11.52M | -75.96M |
| Income Tax Expenses | -15.00K | -82.00K | -- | -18.00K | 7.00K |
| Earnings from Continuing Operations | -38.48M | -46.76M | -56.86M | -11.50M | -75.97M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.48M | -46.76M | -56.86M | -11.50M | -75.97M |
| EBIT | -29.61M | -33.66M | -38.90M | 15.08M | -47.47M |
| EBITDA | -28.34M | -32.03M | -37.00M | 16.98M | -45.57M |
| EPS Basic | -2.94 | -5.35 | -6.70 | -1.36 | -9.08 |
| Normalized Basic EPS | -1.84 | -3.04 | -3.48 | 0.51 | -4.10 |
| EPS Diluted | -2.94 | -5.35 | -6.70 | -1.36 | -9.08 |
| Normalized Diluted EPS | -1.84 | -3.04 | -3.48 | 0.51 | -4.10 |
| Average Basic Shares Outstanding | 13.08M | 8.73M | 8.49M | 8.46M | 8.36M |
| Average Diluted Shares Outstanding | 13.08M | 8.73M | 8.49M | 8.46M | 8.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |